January 18, 2017 / 12:16 PM / a year ago

BRIEF-Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935

Jan 18 (Reuters) - Takeda Pharmaceutical Co Ltd:

* Takeda and Ovid Therapeutics announce innovative clinical development, commercialization collaboration for TAK-935 in rare pediatric epilepsies

* Takeda Pharmaceutical says received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of TAK-935

* Takeda Pharmaceutical says Takeda will lead commercialization in Japan, and has the option to lead in asia and other selected geographies

* Takeda Pharmaceutical says Cos to share in development and commercialization costs on 50/50 basis; if successful, will share in profits on 50/50 basis

* Takeda Pharmaceutical says if mutually agreed, additional orphan central nervous system indications may also be pursued

* Takeda Pharmaceutical says Ovid will lead clinical development activities and commercialization of TAK-935 in the U.S., Europe, Canada and Israel

* Takeda pharmaceutical says additional financial details were not disclosed

* Takeda pharmaceutical says companies expect to initiate a phase 1B/2A study in 2017 in patients with rare epileptic encephalopathies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below